Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Sickle Cell Disease (Sep 2020)

Posted by Matt Breese on Sep 25, 2020

Find me on:

According to our recent payer coverage analysis for sickle cell disease treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for sickle cell disease treatments shows that under the pharmacy benefit, about 22% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Sickle Cell Disease-3Q2020-updatedData snapshot as of Q3 2020

Trends: In November 2019, the FDA gave accelerated approval to Global Blood Therapeutics, Inc.'s Oxbryta (voxelotor) for the treatment of sickle cell disease in people at least 12 years old. The company says it's the first FDA-approved treatment that targets the root cause of the disease.  

To read the full Reality Check on Sickle Cell Disease treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing